Revenue → Gross profit: $15.9BPharmaceutical → Revenue: $13.2BRevenue → Cost of revenue: $7.8BMedical devices → Revenue: $6.8BGross profit → SG&A: $6.5BGross profit → Operating profit: $5.3BImmunology → Pharmaceutical: $4.1BOncology → Pharmaceutical: $3.9BGross profit → R&D: $3.8BConsumer health → Revenue: $3.8BOperating profit → Net profit: $3.4BSurgery → Medical devices: $2.4BOrthopaedics → Medical devices: $2.1BNeuroscience → Pharmaceutical: $1.7BInfectious diseases → Pharmaceutical: $1.5BOperating profit → Other: $1.2BVision → Medical devices: $1.1BInterventional → Medical devices: $1.1BOther pharma → Pharmaceutical: $1.0BPulmonary → Pharmaceutical: $0.9BOperating profit → Tax: $0.7BGross profit → In-process R&D: $0.2BGross profit → Restructuring: $0.1BInterest income → Net profit: $0.1BConsumer health: $3.8BRevenue: $23.7BImmunology: $4.1BPharmaceutical: $13.2BInfectious diseases: $1.5BNeuroscience: $1.7BOncology: $3.9BPulmonary: $0.9BOther pharma: $1.0BMedical devices: $6.8BInterventional: $1.1BOrthopaedics: $2.1BSurgery: $2.4BVision: $1.1BGross profit: $15.9BCost of revenue: $7.8BOperating profit: $5.3BSG&A: $6.5BR&D: $3.8BIn-process R&D: $0.2BRestructuring: $0.1BInterest income: $0.1BNet profit: $3.5BOther: $1.2BTax: $0.7Bcreated with SankeyArt.comConsumer health$3.8B3% Y/YRevenue$23.7B-4% Y/YImmunology$4.1BPharmaceutical$13.2B-8% Y/YInfectious diseases$1.5BNeuroscience$1.7BOncology$3.9BPulmonary$0.9BOther pharma$1.0BMedical devices$6.8B-1% Y/YInterventional$1.1BOrthopaedics$2.1BSurgery$2.4BVision$1.1BGross profit$15.9B-5% Y/YCost of revenue$7.8B-2% Y/YOperating profit$5.3B9% Y/YSG&A$6.5B-9% Y/YR&D$3.8B-19% Y/YIn-process R&D$0.2BRestructuring$0.1BInterest income$0.1BNet profit$3.5B-26% Y/YOther$1.2B$0.0B 2021Tax$0.7B$0.1B 2021Johnson & Johnson Q4 FY22 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3